Fresenius Kabi Canada announced the recent Health Canada Notice of Compliance (NOC) for OtulfiTM, an ustekinumab biosimilar indicated for Crohn's disease, ulcerative colitis, plaque psoriasis and active psoriatic arthritis in adult patients. This milestone comes just a few months after the NOC approval of Tyenne® (tocilizumab) and Idacio® (adalimumab) Citrate-free formulation. Fresenius Kabi, an operating company of Fresenius, is further continuing its momentum in Canada, striving to expand its strong Biopharma portfolio. This expansion is a substantial cornerstone of #FutureFresenius.
"This is Fresenius Kabi Canada's third immunology biosimilar product approval, an important milestone on our pathway to expand our biopharma portfolio in Canada. This achievement underscores our commitment to improving patient care across the country." said Darius Panaligan Sr. Vice President Commercial, Fresenius Kabi Biopharma, EU & ROW.
OtulfiTM will provide Canadians with a cost-effective alternative, which helps to ensure healthcare in Canada is accessible and affordable for all patients. All ten provinces have adopted the transition to biosimilars, and Fresenius Kabi is committed to continue providing further cost-effective solutions such as OtulfiTM.
"We are very proud to be introducing an affordable alternative ustekinumab treatment option for patients living with inflammatory and immune diseases." said Abhi Bhoite, Sr. Director and Head of Commercial, Fresenius Kabi Biopharma, Canada.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox!
Sign up now!